Literature DB >> 3209184

Primary pulmonary lymphoma: a re-appraisal of its histogenesis and its relationship to pseudolymphoma and lymphoid interstitial pneumonia.

B J Addis1, E Hyjek, P G Isaacson.   

Abstract

The clinical, morphological and immunohistochemical features of 15 cases of pulmonary lymphoproliferative disease are described. The diagnosis of primary pulmonary lymphoma was based in 13 cases on the demonstration of light chain restriction and in two cases on morphological characteristics. Many patients had a prolonged clinical course without significant clinical or radiographic deterioration, a feature associated with malignant lymphomas of mucosa-associated lymphoid tissue in other sites. Lymphoepithelial lesions were characteristic and malignant cells had the features of centrocyte-like cells, similar to those described in gastric and salivary gland lymphomas. Germinal centres were present in three cases: some were partially overgrown by centrocyte-like cells but residual polyclonal follicle centre cells and dendritic reticulum cells were still detectable. It is suggested that primary pulmonary lymphoma arises from centrocyte-like cells normally present in bronchus-associated lymphoid tissue. In addition to the malignant population, reactive follicles and polytypic plasma cells are frequently present and may prejudice interpretation of immunohistochemical features. In the light of these findings, cases previously diagnosed as pseudolymphoma or lymphoid interstitial pneumonia require careful assessment and the majority are, in reality, examples of primary pulmonary lymphomas.

Entities:  

Mesh:

Year:  1988        PMID: 3209184     DOI: 10.1111/j.1365-2559.1988.tb02000.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  25 in total

Review 1.  Non-neoplastic pulmonary lymphoid lesions.

Authors:  W D Travis; J R Galvin
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Nodular pulmonary amyloidosis occurring in association with pulmonary lymphoma.

Authors:  C J Davis; E G Butchart; A R Gibbs
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

Review 3.  [Idiopathic interstitial pneumonias: from classification to diagnostic work-up].

Authors:  C Müller-Mang; L Stiebellehner; K Schmid; A Bankier
Journal:  Radiologe       Date:  2007-05       Impact factor: 0.635

4.  Primary pulmonary lymphoma diagnosed by gene rearrangement: report of a case.

Authors:  H Miura; O Taira; O Uchida; N Kajiwara; H Kato
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  Malignant lymphoma of the gastrointestinal tract and mesentery. A clinico-pathologic study of the significance of histologic classification. NHL Study Group of the Comprehensive Cancer Center West.

Authors:  J H van Krieken; R Otter; J Hermans; K van Groningen; P J Spaander; M M van de Sandt; J F Keuning; P M Kluin
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

6.  Mucosa associated lymphoma of the lung.

Authors:  P H Bolton-Maggs; A Colman; G R Dixon; M W Myskow; J G Williams; R J Donnelly; C R Hind
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

Review 7.  Forty years literature review of primary lung lymphoma.

Authors:  Haralabos Parissis
Journal:  J Cardiothorac Surg       Date:  2011-03-03       Impact factor: 1.637

8.  Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach.

Authors:  J K Chan; C S Ng; P G Isaacson
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

9.  Human tonsil intraepithelial B cells: a marginal zone-related subpopulation.

Authors:  M Morente; M A Piris; J L Orradre; C Rivas; R Villuendas
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

Review 10.  Primary dural mucosa-associated lymphoid tissue-type lymphoma: case report and review of the literature.

Authors:  M Rottnek; J Strauchen; F Moore; S Morgello
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.